Cargando…
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune pati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646968/ https://www.ncbi.nlm.nih.gov/pubmed/34862313 http://dx.doi.org/10.1136/rmdopen-2021-002019 |
_version_ | 1784610528279134208 |
---|---|
author | Assawasaksakul, Theerada Sathitratanacheewin, Seelwan Vichaiwattana, Preeyaporn Wanlapakorn, Nasamon Poovorawan, Yong Kittanamongkolchai, Wonngarm |
author_facet | Assawasaksakul, Theerada Sathitratanacheewin, Seelwan Vichaiwattana, Preeyaporn Wanlapakorn, Nasamon Poovorawan, Yong Kittanamongkolchai, Wonngarm |
author_sort | Assawasaksakul, Theerada |
collection | PubMed |
description | Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune patients with rheumatic disease. A third-dose SARS-CoV-2 vaccination in immunosuppressed population is recommended in order to improve immune response. However, the data were limited to those initially received mRNA or viral vector SARS-CoV-2 vaccine. Thus, we aimed to describe the safety, reactogenicity and immunogenicity of patients with systemic lupus erythematosus (SLE) who received a heterogenous booster SARS-CoV-2 vaccine following the initial CoronaVac inactivated vaccine series. Our findings support that the third booster dose of mRNA or viral vector vaccine following the inactivated vaccine is well tolerated and elicited a substantial humoral and cellular immune response in inactive patients with SLE having maintenance immunosuppressive therapy without interruption of immunosuppressive medications. |
format | Online Article Text |
id | pubmed-8646968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86469682021-12-06 Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series Assawasaksakul, Theerada Sathitratanacheewin, Seelwan Vichaiwattana, Preeyaporn Wanlapakorn, Nasamon Poovorawan, Yong Kittanamongkolchai, Wonngarm RMD Open Lupus Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune patients with rheumatic disease. A third-dose SARS-CoV-2 vaccination in immunosuppressed population is recommended in order to improve immune response. However, the data were limited to those initially received mRNA or viral vector SARS-CoV-2 vaccine. Thus, we aimed to describe the safety, reactogenicity and immunogenicity of patients with systemic lupus erythematosus (SLE) who received a heterogenous booster SARS-CoV-2 vaccine following the initial CoronaVac inactivated vaccine series. Our findings support that the third booster dose of mRNA or viral vector vaccine following the inactivated vaccine is well tolerated and elicited a substantial humoral and cellular immune response in inactive patients with SLE having maintenance immunosuppressive therapy without interruption of immunosuppressive medications. BMJ Publishing Group 2021-12-03 /pmc/articles/PMC8646968/ /pubmed/34862313 http://dx.doi.org/10.1136/rmdopen-2021-002019 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Lupus Assawasaksakul, Theerada Sathitratanacheewin, Seelwan Vichaiwattana, Preeyaporn Wanlapakorn, Nasamon Poovorawan, Yong Kittanamongkolchai, Wonngarm Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series |
title | Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series |
title_full | Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series |
title_fullStr | Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series |
title_full_unstemmed | Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series |
title_short | Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series |
title_sort | immunogenicity, safety and reactogenicity of a heterogeneous booster following the coronavac inactivated sars-cov-2 vaccine in patients with sle: a case series |
topic | Lupus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646968/ https://www.ncbi.nlm.nih.gov/pubmed/34862313 http://dx.doi.org/10.1136/rmdopen-2021-002019 |
work_keys_str_mv | AT assawasaksakultheerada immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries AT sathitratanacheewinseelwan immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries AT vichaiwattanapreeyaporn immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries AT wanlapakornnasamon immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries AT poovorawanyong immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries AT kittanamongkolchaiwonngarm immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries |